

CURRICULUM VITAE

Name: Maryalice Stetler-Stevenson, M.D., Ph.D.

Citizenship: United States

Education:

1975 - B.S. (Biology), Albright College, Reading, Pennsylvania

1981 - Ph.D. (Physiology), Northwestern University, Evanston, Illinois

1984 - M.D. (Medicine), Northwestern University Medical School, Chicago, Illinois

Board Certification:

Anatomic Pathology, American Board of Pathology, August 27, 1990

Brief Chronology of Employment:

1/85 - 6/87 - Housestaff, Pathology Resident, Northwestern Memorial Hospital, McGaw Medical Center, Chicago, Illinois

7/87 - 6/89 - Expert, Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

7/89 - 9/92 - Senior Staff Fellow, Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

7/89 - date - Director, Flow Cytometry Laboratory, Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

9/92 - date - Medical Officer, Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

Societies:

Clinical Cytometry Society

European Society for Clinical Cellular Analysis

Maryalice Stetler-Stevenson, M.D., Ph.D.

Honors and Other Special Scientific Recognition:

B.S., Magna cum laude, Albright College, 1975
Kemper Foundation Medical Scholar
Frank and Louise Graff Foundation Scholar
NIH Training Grant #T35AI07224-02 for Medical Student Short Term Research
Honorable Mention- Castleman Award
Distinguished Alumnus Award, Albright College, 2000
NCI Mentor of Merit Award, 2005
Clinical Laboratory Standards Institute Leadership and Service Award, 2008
Wallace H. Coulter Award, Clinical Cytometry Society, 2010
NIH Director's Award, 2017

Research Interest: Flow cytometric immunophenotyping in diagnosis of hematological malignancies

Present Address: 10 Center Dr, Room 3S235G
Bethesda, MD, 20892

Maryalice Stetler-Stevenson, M.D., Ph.D.

BIBLIOGRAPHY

1. Stetler-Stevenson, M. A., Yang, D. C., McCartney, L., Peterson, D., Lipkowski, A., and Flouret, G.: Synthesis and characterization of the metabolic products of LHRH breakdown by renal tissue. In Brunfeldt, K. (Ed.): *Peptides*. Copenhagen, Scriptor, 1981, p. 725.
2. Stetler-Stevenson, M. A., Yang, D. C., Lipkowski, A., McCartney, L., Peterson, D. R., and Flouret, G.: An approach to the elucidation of metabolic breakdown products of the luteinizing hormone releasing hormone. *J. Med. Chem.* 24:688, 1981.
3. Stetler-Stevenson, M. A., Carone, F., Flouret, G., and Peterson, D.: On the metabolic breakdown of LHRH by renal tissue. In Rich, D. H. and Gross, E. (Eds.): *Peptides*. Rockford, IL, Pierce Chemical Co., 1981, p. 821.
4. Stetler-Stevenson, M. A., Flouret, G., and Peterson, D. R.: Handling of luteinizing hormone releasing hormone by renal proximal tubular segments in vitro. *Am. J. Physiol.* 241:F117, 1981.
5. Stetler-Stevenson, M. A., Flouret, G., Nakamura, S., Gulczynski, B., and Carone, F.: In vivo metabolism of tritiated LHRH by the whole kidney and individual tubules of rats. *Am. J. Physiol.* 244:F628, 1983.
6. Flouret, G., Stetler-Stevenson, M. A., Carone, F., and Peterson, D.: Enzymatic degradation of LHRH and analogs. In Vickery, B. H., Lester, J. J., Carbin, A., and Hafezese, M. (Eds.): *LHRH and Its Analogs—A New Class of Contraceptives and Therapeutic Agents*. M.T.P. Press Limited, 1984, p. 397.
7. Carone, F., Stetler-Stevenson, M. A., May, V., LaBarbera, A., and Flouret, G.: Differences between in vitro and in vivo degradation of LRHR by rat brain and other organs. *Am. J. Physiol.* 253:E317, 1987.
8. Stetler-Stevenson, M. A., Raffeld, M., Cohen, P., and Cossman, J.: Detection of occult follicular lymphoma by specific DNA amplification. *Blood* 72:1822-1825, 1988.
9. Cossman, J., Stetler-Stevenson, M. A., Rizzi, R., and Raffeld, M.: The role of molecular genetics in the diagnosis of lymphoma. In Dammacco, F. (Ed.): *Immunoregulation and Lymphoproliferative Disorders: Basic and Clinical Aspects*. Milan, Edi-Ermes, 1989, pp. 133-138.
10. Stetler-Stevenson, M. A. and Cossman, J.: Involvement of the bcl-2 gene in Hodgkin's disease. *J. Natl. Cancer Inst.* 82:855-858, 1990.

Maryalice Stetler-Stevenson, M.D., Ph.D.

BIBLIOGRAPHY (Cont'd)

11. Cossman, J., Stetler-Stevenson, M., Medeiros, L. J., and Raffeld, M.: Molecular genetics of lymphoproliferative processes. In DeVita, V. T., Jr., Hellman, S S Hellman, S Hellman, SSHellman, S., and Rosenberg, S. (Eds.): *Important Advances in Oncology*. Philadelphia, J. B. Lippincott Co., 1990, pp. 101-113.
12. Medeiros, L. J., Lardelli, P., Stetler-Stevenson, M., Longo, D. L., and Jaffe, E. S.: Genotypic analysis of diffuse, mixed cell lymphomas: Comparison with morphologic and immunophenotypic findings. *Am. J. Clin. Pathol.* 95:547-555, 1991.
13. Lardelli, P., Swaby, R. F., Medeiros, L. J., Jaffe, E. S., Rizzi, R., and Stetler-Stevenson, M.: Determination of lineage and clonality in diffuse lymphomas using the polymerase chain reaction technique. *Hum. Pathol.* 22:685-689, 1991.
14. Medeiros, L. J., Bhagat, S. K. M., Naylor, P., Fowler, D., Jaffe, E. S., and Stetler-Stevenson, M.: Malignant thymoma associated with T-cell lymphocytosis. A case report with immunophenotypic and gene rearrangement analysis. *Arch. Pathol. Lab. Med.* 117:279-283, 1993.
15. Sneller, M. C., Straus, S. E., Jaffe, E. S., Jaffe, J. S., Fleisher, T. A., Stetler-Stevenson, M. and Strober, W.: A novel lymphoproliferative/autoimmune syndrome resembling murine lpr/gld disease. *J. Clin. Invest.* 90: 334-341, 1992.
16. Jaffe, E.S., Raffeld, M., Medeiros, L.J., and Stetler-Stevenson, M.: An overview of the classification of non-Hodgkin's lymphomas: An integration of morphological and phenotypical concepts. *Cancer Res.* (suppl.) 52:5447s-5452s, 1992.
17. Kaur, G., Stetler-Stevenson, M., Sebers, S., Worland, P., Sedlacek, H., Myers, C., Czech, J., Naik, R., and Sausville, E. A.: Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275. *J. Natl. Cancer Inst.* 18:1710-1715, 1992.
18. Medeiros, L. J. and Stetler-Stevenson, M.: Composite B-cell and T-cell lymphoma. Coincidental occurrence or related neoplasms? *Am. J. Clin. Pathol.* 94:387-389, 1992.
19. Stetler-Stevenson, M.: The t(14;18) translocation in Hodgkin's disease. *J. Natl. Cancer Inst.* 84:1770-1771, 1992.
20. Mimnaugh, E. G., Monti, E., Sebers, S., Stetler-Stevenson, M., and Sinha, B. K.: Synergistic antiproliferative effects of the combination of interleukin-1a and doxorubicin against human melanoma cells. *Oncol. Res.* 4:401-412, 1992.

Maryalice Stetler-Stevenson, M.D., Ph.D.

BIBLIOGRAPHY (Cont'd)

21. Bhagat, S. K. M., Medeiros, L. J., Weiss, L. M., Wang, J., Raffeld, M., and Stetler-Stevenson, M.: bcl-2 expression in Hodgkin's disease. Correlation with the t(14;18) translocation and Epstein-Barr virus. *Am. J. Clin. Pathol.* 99:604-608, 1993. *Am. J. Clin. Pathol.* 99:604-608, 1993.
22. Seynaeve, C. M., Stetler-Stevenson, M., Sebers, S., Kaur, G., Sausville, E. A., and Worland, P. J.: Cell cycle arrest and growth inhibition by the protein kinase antagonist UCN-01 in human breast carcinoma cells. *Cancer Res.* 53:2081-2086, 1993.
23. Wang, J., Raffeld, M., Medeiros, L. J., Longo, D. L., Jaffe, E. S., Duffey, P., and Stetler-Stevenson, M.: Follicular center cell lymphoma with the t(14;18) translocation in which the rearranged BCL-2 gene is silent. *Leukemia* 7:1834-1839, 1993.
24. Metz, D. C., Kuchnio, M., Fraker, D. L., Venzon, D. J., Merino, M., Jensen, R. T., and Stetler-Stevenson, M.: Flow cytometry and Zollinger-Ellison syndrome: relationship to clinical course. *Gastroenterology* 105:799-813, 1993.
25. Schwartzentruber, D. J., Stetler-Stevenson, M., Rosenberg, S. A., and Topalian, S. L.: Tumor infiltrating lymphocytes derived from B cell lymphomas secrete GM-CSF and TNF- α in response to autologous tumor stimulation. *Blood* 82:1204-1211, 1993.
26. Worland, P. J., Kaur, G., Stetler-Stevenson, M., Sebers, S., Sartor, O., and Sausville, E. A.: Alteration of the phosphorylation state of p34^{cdc2} kinase by the flavone L86-8275 in breast carcinoma cells: Correlation with decreased H1 kinase activity. *Biochem. Pharmacol.* 46:1831-1840, 1993.
27. Kuchnio, M., Sausville, E. A., Jaffe, E. S., GrT., Foss, F. M., McClanan, M. and Stetler-Stevenson, M.: Flow cytometric detection of neoplastic T cells in patients with mycosis fungoides based upon levels of T-cell receptor expression. *Am. J. Clin. Pathol.* 102:856-860, 1994.
28. Nicholson, J. K. A., Rao, P. E., Calvelli, T., Stetler-Stevenson, M., Browning, S. W., Yeung, L., and Marti, G. E.: Artifactual staining of monoclonal antibodies in two-color combinations is due to an immunoglobulin in the serum and plasma. *Cytometry* 18:140-146, 1994.
29. Wersto, R. P. and Stetler-Stevenson, M.: Debris compensation of DNA histograms and its effect on S-phase analysis. *Cytometry* 20:43-52, 1995.

BIBLIOGRAPHY (Cont'd)

30. Cohen, R., Jaffe, E., Stetler-Stevenson, M., Sausville, E. A., DeNigris, E. C., Woodworth, T., and Foss, F. M.: Bilateral adrenal hemorrhage and adrenal insufficiency in a patient with lymphomatous adrenal infiltration following administration of a fusion toxin (DAB486 interleukin-2). *J. Immunotherap. Emphasis Tumor Immunol.* 16:229-233, 1994.
31. O'Leary, T. J. and Stetler-Stevenson, M.: Diagnosis of t(14;18) by polymerase chain reaction: The natural evolution of a laboratory test. *Arch. Pathol. Lab. Med.* 118:789-790, 1994.
32. Hollingsworth, H. C., Stetler-Stevenson, M., Gagneten, D., Kingma, D. W., Raffeld, M., and Jaffe, E. S.: Immunodeficiency-associated malignant lymphoma - three cases showing genotypic evidence of both T- and B-cell lineages. *Am. J. Surg. Pathol.* 18:1092-1101, 1994.
33. Foss, F. M., Koc, Y., Stetler-Stevenson, M., Nguyen, D. T., O'Brien, M. C., Turner, and Sausville, E. A.: Costimulation of cutaneous T-cell lymphoma cells by interleukin-7 and interleukin-2: Potential autocrine or paracrine effectors in the Sezary syndrome. *J. Clin. Oncol.* 12:326-335, 1994.
34. Foss, F. M., Borkowski, T. A., Gilliom, M., Stetler-Stevenson, M., Jaffe, E.S., Figg, W.D., Tompkins, A., Bastian, A., Nylén, P., Woodworth, T., Udey, M.C., and Sausville, E.A.: Chimeric fusion protein toxin DAB486IL-2 in advanced mycosis fungoides and the sezary syndrome: Correlation of activity and interleukin-2 receptor expression in a phase II study. *Blood* 84:1765-1774, 1994.
35. Roth, M. J., Medeiros, L. J., Elenitoba-Johnson, K., Kuchnio, M., Jaffe, E. S., and Stetler-Stevenson, M.: Extramedullary myeloid cell tumors: An immunohistochemical study of 29 cases using routinely fixed and processed paraffin-embedded tissue sections. *Arch. Pathol. Lab. Med.* 119:790-798, 1995.
36. Sausville, E. A., Headlee, D., Stetler-Stevenson, M., Jaffe, E.S., Solomon, D., Figg, W.D., Herdt, J., Kopp, W.C., Rager, H., Steinberg, S.M., Ghetie, V., Schindler, J., Uhr, J., Whittes, R.E., and Vitetta, E. S.: Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: A phase I study. *Blood* 85:3457-3465, 1995.
37. Stetler-Stevenson, M., Medeiros, L. J., and Jaffe, E. S.: Immunophenotypic methods and findings in the diagnosis of lymphoproliferative diseases. In Jaffe, E. S. (Ed.): *Surgical Pathology of the Lymph Nodes and Related Organs*. W. B. Saunders Co., Philadelphia, PA, 1995.

Maryalice Stetler-Stevenson, M.D., Ph.D.

BIBLIOGRAPHY (Cont'd)

38. Stetler-Stevenson, M. and Marti, G. E.: Flow cytometry: More than just cell sorting; *Hot Methods Clinic. NIH Catalyst* 3:12, 1995.
39. Kang, Y. K., Zhan, Z., Regis, J., Alvarez, M., Robey, R., Meadows, B., Dickstein, B., Lee, J. S., Otsuki, T., Stetler-Stevenson, M., et al.: Expression of mdr-1 in refractory lymphoma: quantitation by polymerase chain reaction and validation of the assay. *Blood* 86:1515-1524, 1995.
40. Stetler-Stevenson, M., and Wersto, R. P.: The Ross article reviewed. *Oncology* 10:887-888, 1996.
41. Wang, J., Medeiros, L. J., Longo, D, Raffeld, M., Duffey, P. L., Jaffe, E. S., and Stetler-Stevenson, M.: Use of the polymerase chain reaction technique to determine c-myc expression in follicular center cell lymphoma. *Diagn. Mol. Pathol.* 5:20-25, 1996.
42. Stone, M.J., Sausville, E.A., Fay, J.W., Headlee, D., Collins, R.H., Figg, W.D., Stetler-Stevenson, M., Jain, V., Jaffe, E.S., Solomon, D., Lush, R.M., Senderowicz, A., Ghetie, V., Schindler, J., Uhr, J., and Vitetta, E.S.: A phase II study of boluss vs continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA in patients with B cell lymphoma. *Blood* 88:1188-1197, 1996.
43. Stetler-Stevenson, M. and Lim, M.: Use of the polymerase chain reaction technique to detect the t(14;18) translocation in lymphoid tissue. In Hanausek, M. (Ed.): *Tumor Marker Protocols*, Vol. 14. Totowa, New Jersey, Humana Press, 1997.
44. Fukushima P. I., Nguyen, P. K. T., O'Grady, P., and Stetler-Stevenson, M.: Flow cytometric analysis of kappa and lambda light chain expression in evaluation of specimens for B-cell neoplasia. *Cytometry* 26:243-252, 1996.
45. Stetler-Stevenson, M., Mansoor, A., Lim, M., Fukushima, P., Kehrl, J., Marti, G., Ptaszynski, K., Wang, J., and Stetler-Stevenson, W. G.: Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases (TIMPs) in reactive and neoplastic lymphoid cells. *Blood* 89:1708-1715, 1997.
46. Mansoor, A., Stetler-Stevenson, M., Li, R. Z., Frekko, K., Weiss, W., Ahmad, M., Khan, A. H., Mushtaq, S., Saleem, M., Raffeld, M., Kingma, D. W., and Jaffe, E. S.: Prevalence of Epstein-Barr viral sequences and EBV LMP1 oncogene deletions in Burkitt's lymphoma from Pakistan: Epidemiological correlations. *Hum. Pathol.* 28:283-288, 1997.

Maryalice Stetler-Stevenson, M.D., Ph.D.

BIBLIOGRAPHY (Cont'd)

47. Cooke, C. B., Krenacs, L., Stetler-Stevenson, M., Greiner, T. Raffeld, M., Kingma, D. W., Abruzzo, L., Frantz, C., Kaviani, M., and Jaffe, E. S.: Hepatosplenic T-cell lymphoma: A distinct clinicopathologic entity of cytotoxic gamma delta T-cell origin. *Blood* 88:4265-4274, 1996.
48. Gray, J. X., Haino, M., Roth, M. J., Maguire, J. E., Jensen, P. N., Yarme, A., Stetler-Stevenson, M., Siebenlist, U., and Kelly, K.: CD97 is a processed, seven-transmembrane, heterodimeric receptor associated with inflammation. *J. Immunol.* 157:5438-5447, 1996.
49. Jacot, T. A., Striker, G. E., Stetler-Stevenson, M., and Striker, L. J.: Mesangial cells from transgenic mice with progressive glomerulosclerosis exhibit stable, phenotypic changes including undetectable MMP-9 and increased type IV collagen. *Lab. Invest.* 75:791-799, 1996.
50. Liu, Z. H., Striker, G. E., Stetler-Stevenson, M., Fukushima, P., Patel, A., and Striker, L.J.: TNF-alpha and IL-1 alpha induce mannose receptors and apoptosis in glomerular mesangial but not endothelial cells. *Am. J. Physiol.* 270:1595-1601, 1996.
51. Bartosova, Z., Pirsell, M., Reinhold, W., Stetler-Stevenson, M., Zajac-Kaye, M., May, A., Horak, I. D., and Bohr, V. A.: Gene-specific repair in human CD4+ lymphocytes reflects transcription and proliferation. *Mutat. Res.* 363:191-199, 1996.
52. Otsuki, T., Kumar, S., Ensoli, B., Kingma, D. W., Yano, T., Stetler-Stevenson, M., Jaffe, E. S., and Raffeld, M.: Detection of HHV-8/KSHV DNA sequences in AIDS-associated extranodal lymphoid malignancies. *Leukemia* 10:1358-1362, 1996.
53. Senderowicz, A. M., Vitetta, E., Headlee, D., Ghetie, V., Uhr, J. W., Figg, W. D., Lush, R., Stetler-Stevenson, M., Kershaw, G., Kingma, D.W., Jaffe, E.S., and Sausville, E.A.: Complete sustained response of a refractory, post-transplantation, large B-cell lymphoma to an anti-CD22 immunotoxin. *Ann. Int. Med.* 126:882-885, 1997.
54. Baluna, R., Sausville, E. A., Stone, M. J., Stetler-Stevenson, M., Uhr, J. W., and Vitetta, E. S.: Decreases in levels of serum fibronectin predict the severity of vascular leak syndrome in patients treated with ricin A chain-containing immunotoxins. *Clin Cancer Res* 2:1705-1712, 1996
55. Zhou, Q., Stetler-Stevenson, M., and Steeg, P.S.: Inhibition of cyclin D1 expression in human breast carcinoma cells by retinoids *in vitro*.. *Oncogene* 15:107-115, 1997.

Maryalice Stetler-Stevenson, M.D., Ph.D.

BIBLIOGRAPHY (Cont'd)

56. Hartmann, F., Horak, E.M., Cho, C., Lupu, R., Bolen, J. B., Stetler- Stevenson, M., Pfreundschuh, M., Waldmann, T. A., and Horak, I. D.: Effects of the tyrosine-kinase inhibitor geldanamycin on ligand-induced Her-2/neu activation, receptor exmycin on ligand-induced Her-2/neu activation, receptor expression and proliferation of her-2-positive malignant cell lines. *Int. J. Cancer* 70:221-229, 1997.
57. Lamb, L. S., Jr., Robbins, N. F., Abhyankar, S., Joyce, M., Stetler-Stevenson, M., Henslee-Downey, P. J., and Gee, A. P.: Flow cytometric cell sorting used in combination with molecular chimerism analysis for the detection of minimal recurrent leukemia: Good news and bad news. *Bone Marrow Transplantation* 19:1157-1161, 1997.
58. Stetler-Stevenson, M.: Flow cytometric detection of B-cell non-Hodgkin's lymphoma. In Marti, G.E., Vogt, R.F., and Zenger, V.E. (Eds): *Determining the Role of Environmental Exposures as Risk factors for B-cell Lymphoproliferative Disorders*. U.S. Dept HHS, CDC, Atlanta, GA, 1997.
59. Guedez, L., Courtemanch, L., and Stetler-Stevenson, M.: Tissue inhibitor of metalloproteinase (TIMP-1) induces differentiation and an anti-apoptotic phenotype in germinal center B-cells. *Blood* 92:1342, 1998.
60. Molldrem, J., Jiang, Y. J., Stetler-Stevenson, M., Mavroudis, D., Hensel, N., and Barrett, A. J.: Hematological response of patients with myelodysplastic syndrome to antithymocyte globulin (ATG) is associated with loss of lymphocyte-mediated inhibitor of CFV-GM and alterations in T-cell receptor Vb profiles. *Br. J. Haem.* 102:1314, 1998.
61. Nicholson, J. K. A. and Stetler-Stevenson, M.: Quantitative fluorescence: To count or not to count. Is that the question? *Cytometry* 34:203, 1998.
62. Lim, M. S., Straus, S. E., Dale, J. K., Fleisher, T., Stetler-Stevenson, M. , Strober, W., Sneller, M. C., Puck, J. M., Lenardo, M. J., Elenitoba-Johnson, K. S. J., Lin, A. Y., Raffeld, M., and Jaffe, E.: Pathologic findings in human autoimmune lymphoproliferative syndrome. *Am. J. Pathol.* 153:1541-1550, 1998.
63. Borowitz, M. J., Bray, R., Gascoyne, R., Melnick, S., Parker, J. W., Picker, L., and Stetler-Stevenson, M.: U.S.-Canadian consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: Data analysis and interpretation. *Cytometry (CCC)* 30:236-244, 1997.
65. Guedez, L., Stetler-Stevenson, W. G., Wolff, L., Wang, J., Fukushima, P., Mansoor, A., and Stetler-Stevenson, M.: In vitro suppression of programmed cell death of B-cells by tissue inhibitor of metalloproteinases-1 (TIMP-1). *J. Clin. Invest.* 102:2002-2010, 1998.

Maryalice Stetler-Stevenson, M.D., Ph.D.

BIBLIOGRAPHY (Cont'd)

66. Wellmann, A., Doseeva, V., Butscher, W., Raffeld, M., Fukushima, P., Stetler Stevenson, M., and Gardner, K.: The activated anaplastic lymphoma kinase increases cellular proliferation and oncogene up-regulation in rat 1a fibroblasts. *FASEB J.* 11:965-972, 1997.
67. Simsir, A., Fetsch, P., Stetler-Stevenson, M., and Abati, A.: Immunophenotypic analysis of non-Hodgkin's lymphomas in cytologic specimens: A correlative study of immunocytochemical and flow cytometric techniques. *Diagn. Cytopathol* 20:278-84, 1999.
68. McClanahan, J., Fukushima, P and Stetler-Stevenson, M. : Increased peripheral blood gamma delta T-cells in patients with lymphoid neoplasia: A diagnostic dilemma in flow cytometry. *Cytometry* 38:280-285,1999.
69. Stetler-Stevenson, M.: Novel methods in detection of minimal residual non-Hodgkin's lymphoma. *Cytotherapy* 1:336-34, 1999.
70. Kreitman, R.J., Wilson, W., Robbins, D., Margulies, I., Stetler-Stevenson, M., Waldman, T. A., and Pastan, I.: Responses in refractory hairy cell leukemia to a recombinant immunotoxin, *Blood* 94: 3340-3348, 1999.
71. Lim, MS, Guedez, L., Stetler-Stevenson, W., Stetler-Stevenson, M.: Tissue inhibitor of metalloproteinase-2 induces apoptosis in human T lymphocytes. *Ann NY Acad Sci* 878:522-523,1999.
72. Xie, X.Y., Sorbara, L., Kreitman, R. J., Fukushima, P.I., Kingma, D.W., and Stetler-Stevenson, M.: Development of Lymphoproliferative Disorder of Granular Lymphocytes in Association with Hairy Cell Leukemia. *Leukemia and Lymphoma* 37:97-104, 2000.
73. Xie, X.Y., Filie, A.C., Jasper, G.A., Fukushima, P.I. and Stetler-Stevenson, M.: Diagnosis of unexpected acute myeloid leukemia and chronic lymphocytic leukemia: A case report demonstrating the perils of restricted panels in flow cytometric immunophenotyping. *Cytometry* , 42:114-117, 2000.
74. Messmann, R.A., Vitetta, E.S., Headlee, D., Senderowicz, A.M., Figg, W.D., chindler, J., Michiel, D.F., Creekmore, S., Steinberg, S.M., Kohler, D., Jaffe, E.S., Stetler-Stevenson, M., Chen, H., Ghetie, V., and Sausville, E.A.: A phase I study of combination therapy with immunotoxin IgG-HD37-dgA and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B-cell lymphoma, *Clinical Cancer Research* 6:1302-1313, 2000.

Maryalice Stetler-Stevenson, M.D., Ph.D.

BIBLIOGRAPHY (Cont'd)

75. Zhou, Q., Wulfkuhle, J., Ouatas, T., Fukushima, P., Stetler-Stevenson, M., Miller, F.R., and Steeg, P.S. : Cyclin D1 overexpression in a model of human breast premalignancy: preferential stimulation of anchorage-independent but not anchorage dependent growth is associated with cdk2 activity. *Breast Cancer Research and Treatment* 59:27-39, 2000.
76. Robbins, D.H., Margulies, I., Stetler-Stevenson, M., and Kreitman, R.J.: Hairy cell leukemia, a B-cell neoplasm that is particularly sensitive to the cytotoxic effect of anti-Tac(Fv)-PE38 (LMB2). *Clinical Cancer Research* 6:693-700, 2000.
77. Zou, Q, Fukushima, P., DeGraff, W, Mitchell, JB, Stetler-Stevenson, M, Askenazi, A, Steeg, P: "Radiation and the Apo2L/TRAIL apoptotic pathway preferentially inhibit the colonization of premalignant human breast cells overexpressing cyclin D1. *Cancer Res* 60:2611-2615, 2000.
78. Kreitman, R. J., Margulies, I., Stetler-Stevenson, M., Wang, Q.-C., FitzGerald, D. J. P., and Pastan, I.: Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4 (dsFv)-PE38 toward fresh malignant cells from patients with B-cell leukemias. *Clin Cancer Res* 6:1476-1487, 2000.
79. Kreitman, R.J., Wilson, W.H., White, J.D., Stetler-Stevenson, M., Jaffe, E.S., Giardina, S., Waldman, T.A., Pastan, I.:Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB2) in patients with hematological malignancies. *J. Clin. Oncol* 18:1622-1636, 2000.
80. Lamb, L.S., Harding, S.A., Stetler-Stevenson, M., Best, R., Bridges, K., Koon, R., Henslee-Downey, P.J. Flow cytometry, cytogenetics, and morphologic analysis to detect minimal recurrent leukemia following allogeneic bone marrow transplantation. *Cytometry* 2000; 42: 318.
81. Guede, L. Mansoor, A., Birkedal-Hansen, B., Lim, M.S., Venzon, D., Stetler-Stevenson, W.G., and Stetler-Stevenson, M: TIMP-1 Regulation of IL-10 in B Cell Differentiation and Lymphomagenesis. *Blood*. 97:1796-1802, 2001.
82. Marti, G.E., Stetler-Stevenson, M., and Fleisher, T.: Diagnostic Flow Cytometry In Hematology. In Ed: G. Faguet: *Hematologic Malignancies: Methods and Techniques*, Humana Press, Totowa,N.J., 2001.
83. Stetler-Stevenson, M. and Xie, X.: Flow Cytometric detection of minimal residual lymphoid neoplasia, technique and utility. *Cancer Research Therapy and Control*. 11:11-20, 2001.
84. Stetler-Stevenson, M., Braylan, R.C.: Flow Cytometric Analysis of Lymphomas and Lymphoproliferative Disorders. In Ed: T. Fleisher: *Seminars in Hematology* *Seminars in Hematology* 38:111-123, 2001.

Maryalice Stetler-Stevenson, M.D., Ph.D.

BIBLIOGRAPHY (Cont'd)

85. Guede, McMarlin, A.J., Kingma, D., Bennett, T.A., Stetler-Stevenson, M. and Stetler-Stevenson, W.G. : Tissue inhibitor of metalloproteinase-1 alters the tumorigenicity of Burkitt's lymphoma via divergent effects on tumor growth and angiogenesis. *A.J.P.* 158:1207-1215, 2001.
86. Marti, G.E., Stetler-Stevenson, M., Blessing, J.J.H., Fleisher, T.A: Introduction to Flow Cytometry. *Seminars in Hematology* 38:93-99, 2001.
87. Stetler-Stevenson, M., Arthur, D, Jabbour, N.,Xie, X.Y., Molldrem, J. Barrett, J.A., Venzon, D., and Rick, M.E.: Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome. *Blood* 98: 979-987, 2001
88. Kingma, D.W., Fischette, M., Jasper, G., Imus, P. and Stetler-Stevenson, M.: Composite large granular lymphoproliferative disorder and CD5+ monoclonal B-cell population arising in myelodysplastic syndrome. *Case Studies in Clinical Flow Cytometry* 1(1):2001.
89. Kreitman RJ; Wilson WH; Bergeron K; Raggio M; Stetler-Stevenson M; FitzGerald DJ; Pastan I: Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. *NEJM*, 345: 241-247, 2001.
90. Sauntharajah Y; Molldrem JJ; Rivera M; Williams A; Stetler-Stevenson M; Sorbara L; Young NS; Barrett JA: Coincident myelodysplastic syndrome and T-cell large granular lymphocytic disease: clinical and pathophysiological features. *British Journal of Haematology* 112: 195-200, 2001.
91. Wersto, R.P., Chrest, F.J., Leary, J.F., Morris, C., Stetler-Stevenson, M., Gabrielson, E.: Doublet discrimination in DNA cell-cycle analysis. *Cytometry* 46(5):296-306, 2001.
92. Dahmouch, L, Hijazi, Y., Barnes, E., Stetler-Stevenson, M, Abati, A.: Adult T-cell leukemia/lymphoma. A cytopathologic, immunocytochemical and flow cytometric study. *Cancer (Cancer Cytopathol)* 96:110-6, 2002.
93. Kingma, D.W., Imus, P, Xie, XY, Jasper, G., Sorbara, L, Stewart, C, Stetler-Stevenson, M: CD2 is Expressed by a Sub-Population of Normal B Cells and is Frequently Present in Mature B Cell Neoplasms, *Clinical Cytometry* 50:243-248, 2002.

Maryalice Stetler-Stevenson, M.D., Ph.D.

BIBLIOGRAPHY (Cont'd)

94. Kingma , D.W., Sorbara, L., Kurlander,R., Imus, P., Taubenberger, J.K., Stetler-Stevenson, M. :CD3 negative, clonal lymphoproliferative disorder of granular lymphocytes. *Case Studies in Clinical Flow Cytometry* 1(1):2001
95. Kingma, D.W., Imus, P., Knight, C., Jasper, G.A., Stetler-Stevenson, M. : Variant Hairy Cell Leukemia. *Case Studies in Clinical Flow Cytometry* 2 (2), 2002.
96. Lunning, M. A., Stetler-Stevenson, M., Silberstein, P.T., Zenger, V., Marti, G.E.: Spontaneous (Pathological) Splenic Rupture in Mantle Cell Lymphoma Blastic Variant: Case Report with Literature Review. *Clinical Lymphoma* 3 (2): 2002
97. Sausville, J.E, Salloum, R.G., Sorbara, L., Kingma,D.W., Raffeld, M.D., M., Kreitman, R., Imus, P.D., Venzon, D.,Stetler-Stevenson, M: Minimal Residual Disease Detection in Hairy Cell Leukemia: Comparison of Flow Cytometric Immunophenotyping to Clonal Analysis Using Consensus Primer Polymerase Chain Reaction for the Heavy Chain Gene *AJCP* 119:213-217, 2003.
98. Marti, G.E., Carter, P., Abbasi, F., Wasshington, G.C., Jain, N., Zenger, V.E., Ishibe, N., Goldin, L., Weissman, N., Sgambati, M., Fauget, G., Bertin, P., Vogt, R.F., Slade, B., Noguchi, P.D., Stetler-Stevenson, M., Caporaso, N.: B-cell monoclonal lymphocytosis and B-cell abnormalities in the setting of familial B-cell Chronic Lymphocytic Leukemia. *Cytometry* 52B:1-12, 2003.
99. Stetler-Stevenson, M.: Flow cytometry in lymphoma diagnosis and prognosis: useful ?. *Best Practice & Research Clinical Haematology* 16:583-597, 2003.
100. Luning, M.A., Zenger, V.E., Dreyfus, R., Stetler-Stevenson, M., Rick, M.E., White, T.A., Wilson, W., Marti, G.E.: Albumin enhanced morphometric image analysis in CLL. *Clinical Cytometry*, 57B: 7-14, 2003.
101. Marti, GE, Vogt, RE, Stetler-Stevenson: Identifying the optimal methods for clinical quantitative flow cytometry. *Clinical Cytometry*, 55B(1): 59-60, 2003.
102. Wiestner A, Rosenwald A, Barry TS, Wright G, Davis RE, Henrickson SE, Zhao H, Ibbotson RE, Orchard JA, Davis Z, Stetler-Stevenson M, Raffeld M, Arthur DC, Marti GE, Wilson WH, Hamblin TJ, Oscier DG, Staudt LM: ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. *Blood* ,101 (12): 4944-4951, 2003.

Maryalice Stetler-Stevenson, M.D., Ph.D.

BIBLIOGRAPHY (Cont'd)

103. Haviernik P, Lahoda C, Bradley HL, Hawley TS, Ramezani A, Hawley RG, Stetler-Stevenson M, Stetler-Stevenson WG, Bunting KD: Tissue inhibitor of matrix metalloproteinase-1 overexpression in M1 myeloblasts impairs IL-6-induced differentiation, *Oncogene*, 23 (57): 9212-9219, 2004.
104. Guede L, Martinez A, Zhao S, Vivero A, Pittaluga S, Stetler-Stevenson M, Raffeld M, Stetler-Stevenson WG.: Tissue inhibitor of metalloproteinase 1 (TIMP-1) promotes plasmablastic differentiation of a Burkitt lymphoma cell line: implications in the pathogenesis of plasmacytic/plasmablastic tumors. *Blood*. 2005 Feb 15;105(4):1660-8. Epub 2004 Oct 12.
105. Hegde, U., Filie, A., Little, R.F., Janik, J.E., Grant, N., Steinberg, S.M., Dunleavy, K., Jaffe, E.S., Abati, A., Stetler-Stevenson, M., and Wilson, W.H.: High Incidence of Occult Leptomeningeal Disease Detected by Flow Cytometry in Aggressive B-Cell Lymphomas at Risk of Central Nervous System Involvement: The Role of Flow Cytometry versus Cytology, *Blood*, 105(2): 496-502, 2005.
106. Ahmad, E. , Kingma, D.W., Jaffe, E.S., Schrager, J.A., Janik , J., Wilson, W., Stetler-Stevenson M.: Flow Cytometric Immunophenotypic Profiles of Mature Gama Delta T Cell Malignancies Involving Peripheral Blood and Bone Marrow, *Clinical Cytometry* 67B: 6-12, 2005.
107. Kreitman, R.J., Squires, D.R., Stetler-Stevenson, M., Noel, P., FitzGerald, D.J.P., Wilson, W.H., Pastan, I.: Phase I Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38(BL22) in Patients with B-Cell Malignancies. *J. Clin.Oncol*, 23 (27): 6719-6729, 2005
108. Lawrence S. Lamb Jr, Ronnie Neuberg, Jeff Welsh, Robert Best, Maryalice Stetler-Stevenson, April Sorrell: T-cell lymphoblastic leukemia/lymphoma syndrome with eosinophilia and acute myeloid leukemia. *Clinical Cytometry*, 65B(1):37-41, 2005.
109. Fogarty, P.F., Stetler-Stevenson, M, Pereira, A, Dunbar, C.E. Large Granular Lymphocytic Proliferation-Associated Cyclic Thrombocytopenia, *Amer J Hem* 79:1-3, 2005.
110. Weaver, J.L., Stetler-Stevenson, M. : *Flow Cytometry in the Biomedical Arena*. Medical Biomedical Handbook. Ed Dr John M Walker, Humana Press (2005).
111. Neelapu, S.S., KWAK, L.W., Kobrin, C.B., Reynolds. C.W., Janik, J.E., Dunleavy, K, White, T., Harvey, L., Pennington, R. Stetler-Stevenson, M., Jaffe, E.S., Steinberg, S.M., Gress, R., Hakim, F., Wilson, W.H.: Vaccine induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma, *Nature Medicine*, 11:986-991, 2005.

Maryalice Stetler-Stevenson, M.D., Ph.D.

BIBLIOGRAPHY (Cont'd)

112. Aurran-Schleinitz, T, Telford, W, Perfetto, S, Caporaso, N, Wilson, W, Stetler-Stevenson, MA, Zenger, VE, Abbasi, F,:GE Marti⁷:Identification of a New Monoclonal B Cell Subset in Unaffected First-Degree Relatives in Familial Chronic Lymphocytic Leukemia, *Leukemia*, 19: 2339-2341, 2005.
113. Stetler-Stevenson, M and Schrager, J.A.: Flow Cytometric Analysis in the Diagnosis and Prognosis of Lymphoma and Chronic Leukemias. Carey, JL, Keren, DF, and McCoy, JP (ed). In: *Flow Cytometry in Clinical Diagnosis*. 4th ed, ed. J.P.M. John L. Carey, David F. Keren. 2007, Chicago: ASCP Press.
114. Rosenberg SA, Sportes C, Ahmadzadeh M, Fry TJ, Ngo LT, Schwarz SL, Stetler-Stevenson, M, Morton, KE, Mavroukakis, SA, Morre, M, Buffet, R, Mackall, CL, Gress, RE.: IL-7 Administration to humans leads to expansion of CD8⁺ and CD4⁺ cells but a relative decrease of CD4⁺ T-regulatory cells. *J Immunother* 29:313-319, 2006.
115. Arons E, Margulies I, Sorbara L, Raffeld M, Stetler-Stevenson M, Pastan I, Kreitman RJ.: Minimal residual disease in hairy cell leukemia patients assessed by clone-specific polymerase chain reaction.. *Clin Cancer Res*. 2006 May 1;12(9):2804-11.
116. Schinstine M, Filie AC, Wilson W, Stetler-Stevenson M, Abati A.: Detection of malignant hematopoietic cells in cerebral spinal fluid previously diagnosed as atypical or suspicious. *Cancer*. 2006 Jun 25;108(3):157-62.
117. Arons E, Sorbara L, Raffeld M, Stetler-Stevenson M, Steinberg SM, Liewehr DJ, Pastan I, Kreitman RJ.: Characterization of T-cell repertoire in hairy cell leukemia patients before and after recombinant immunotoxin BL22 therapy. *Cancer Immunol Immunother*. 2006 Sep;55(9):1100-10. Epub 2005 Nov 26.
119. Arons, E, Suntum, T, Sunshine, J, Stetler-Stevenson, M, and Kreitman, RJ: Immunoglobulin light chain repertoire in hairy cell leukemia. *Leukemia Research*. 31 (9):1231-1236, 2007
120. Davis BH, Holden JT, Bene MC, Borowitz MJ, Braylan RC , Cornfield D, Gorczyca W, Lee R, Maiese R, Orfao A, Wells D, Wood BL, Stetler-Stevenson M. 2006 Bethesda International Consensus Recommendations on the Flow Cytometric Immunophenotypic Analysis of Hematolymphoid Neoplasia: Medical Indications, Clinical Cytometry. 72B:S5-S13, 2007
121. Ise T, Nagata S, Kreitman RJ, Wilson WH, Wayne AS, Stetler-Stevenson M, Bishop MR, Scheinberg DA, Rassenti L, Kipps TJ, Kyle RA, Jelinek DF, Pastan I :Elevation of soluble CD307 (IRTA2/FcRH5) protein in the blood and expression on malignant cells of patients

Maryalice Stetler-Stevenson, M.D., Ph.D.

BIBLIOGRAPHY (Cont'd)

with multiple myeloma, chronic lymphocytic leukemia, and mantle cell lymphoma,
LEUKEMIA 21 (1): 169-174 JAN 2007

122. Stetler-Stevenson, M., Ahmad, E, Barnett, D, et al, *Clinical and Laboratory Standards Institute. Clinical Flow Cytometric Analysis of Neoplastic Hematolymphoid Cells; Approved Guideline-Second Edition. CLSI document H43-A2*, ed. M. Stetler-Stevenson, Ahmad, E, Barnett, D, et al. 2007, Wayne, Pennsylvania, 19087-1898 USA: Clinical and Laboratory Standards Institute.
123. Stetler-Stevenson M, Davis BH, Wood, BL, Braylan RC: 2006 Bethesda International Consensus Recommendations on the Flow Cytometric Immunophenotypic Analysis of Hematolymphoid Neoplasia. *Clinical Cytometry* 72B:S3, 2007.
124. Hardy, NM, Grady, C, Pentz, R, Stetler-Stevenson, M, Raffeld, M, Bishop, MR, Caporaso, N, Marti, GE. Bioethical Considerations of Monoclonal B Cell Lymphocytosis: Donor Transfer After Hematopoietic Stem Cell Transplantation, *BJH* 139: 824-831, 2007.
125. Du,X, Ise, T, Nagata, S, Stetler-Stevenson, M, Pastan, I. FCRL1 on chronic lymphocytic leukemia, hairy cell leukemia and B-cell non-Hodgkin's lymphoma as a target of immunotoxins, *Blood*, 111:338-343, 2008.
126. Ahmad, E, Steinberg, SM, Goldin, L, Hess,CJ, Caporaso, N, Kreitman, RJ, Wiestner, A, Wilson, W, White, T, Marti, G, Stetler-Stevenson, M., Immunophenotypic Features Distinguishing Familial Chronic Lymphocytic Leukemia from Sporadic Chronic Lymphocytic Leukemia, *Clinical Cytometry*, 74B: 221-226, 2008
127. Kraan, J., Gratama, J, Haioun, C, Orfao, A, Plonquet, A, Porwit, A, Quijano, S, Stetler-Stevenson, M, Subira, D, Wilson, W, *Flow Cytometric immunophenotyping of Cerebrospinal fluid*. Current Protocols in Cytometry. 2008, Hoboken, NJ: Wiley.
128. Abbasi, F; Longo, NS; Lipsky, PE; Raveche, E; Schleinitz, TA; Stetler-Stevenson, M; Caporaso, N; Marti, G: B-cell repertoire and clonal analysis in unaffected first degree relatives in familial chronic lymphocytic leukaemia kindred, *Brit J Haematol* 139: 820-823, 2007.
129. Du X , Nagata S, Ise T, Stetler-Stevenson M, Pastan I: FCRL1 on chronic lymphocytic leukemia, hairy cell leukemia, and B-cell non-Hodgkin lymphoma as a target of immunotoxins. *Blood*, 111: 338-343 2008.
130. Stetler-Stevenson, M: Flow cytometry of lymphoproliferative disorders and myeloma. *Int J Lab Hematol* 30:23-24, 2008.

131. Arons E, Sontum T , Margulies I, Yuan C, Stetler-Stevenson M, Kreitman RJ: PRAME expression in hairy cell leukemia *Leuk Res* 32:1400-1406, 2008.
132. Kim, YS, Seo, DW , Kong, SK, Lee, JH, Lee, ES, Stetler-Stevenson, M, Stetler-Stevenson, WG : TIMP1 induces CD44 expression and the activation and nuclear translocation of SHP1 during the late centrocyte/post-germinal center B cell differentiation, *CANCER LETTERS* 269:37-45, 2008.
133. Kreitman, R. J., Stetler-Stevenson, M., Margulies, I., Noel, P., FitzGerald, D. J. P., Wilson, W. H., and Pastan, I.: Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia, *J Clin Oncol*: 27:2983-2990, 2009
134. Rizzo, K., Stetler-Stevenson, M., Wilson, W., Yuan, C.M., Novel CD19 Expression in a Peripheral T Cell Lymphoma: A Flow Cytometry Case Report with Morphological Correlation. *Clinical Cytometry*, 76B_142-149, 2009.
135. Jiang, L, Yuan, C, Hubacheck, J, Janik, JE, Wilson, W , Morris, JC, Jasper, GA, Stetler-Stevenson, M: Variable CD52 Expression in Mature T Cell and NK Cell Malignancies: Implications for Alemtuzumab Therapy, *British Journal of Haematology* 145:173-179, 2009.
136. O'Mahony, D, Morris, JC, Stetler-Stevenson, M, Matthews, H , Brown, MR , Fleisher, T, Pittaluga, S, Raffeld, M, Albert, PS, Reitsma, D , Kaucic, K , Hammershaimb, L , Waldmann, TA, Janik. JE : EBV-Related Lymphoproliferative Disease Complicating Therapy with the Anti-CD2 Monoclonal Antibody, Siplizumab, in Patients with T-Cell Malignancies, *Clinical Cancer Research* 15:2514-2522, 2009.
137. Piekarz, R. L., Frye, R., Turner, M., Wright, J. J., Allen, S. L., Kirschbaum, M. H., Zain, J., Prince, H. M., Leonard, J, Geskin, L., Reeder, C., Joske, D., Figg, W. D., Gardner, E. R., Steinberg, S. M., Jaffe, E. J., Stetler-Stevenson, M., Lade, S., Fojo, A. T., Bates, S. E. :A Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin as Monotherapy for Patients with Cutaneous T-cell Lymphoma. *J Clin Oncol*, 2009, 27:5410-5417.
138. Stetler-Stevenson, M. :Flow cytometric immunophenotyping:Emerging as an important diagnostic tool in the evaluation of cytopenic patients, *Leuk Res* 33:1020-1021, 2009.
139. Stetler-Stevenson, M, Yuan, CM: Myelodysplastic syndromes: The role of flow cytometry in diagnosis and prognosis. *Int J Lab Hem* ,31:479-483, 2009.
140. Arun, I, Wulu, J.A., Janik, J. E., Jasper, G. A., C.M. Yuan, C.M., Venzon, D., Stetler-Stevenson, M.. Visual Inspection Versus Quantitative Flow Cytometry to Detect Aberrant CD2 Expression in Malignant T Cells. *Clinical Cytometry*, 78B:169-175, 2010.

141. Shao, H, Yuan, MD, CM, Xi, L, Raffeld, M, Morris, JC, Janik, JE, Stetler-Stevenson, M.: Minimal Residual Disease Detection by Flow Cytometry in Adult T-cell Leukemia/Lymphoma, *AJCP*, 133:592-601, 2010.
142. Arons E, Suntum T, Stetler-Stevenson, M, Kreitman, RJ: VH4-34(+) hairy cell leukemia, a new variant with poor prognosis despite standard therapy. *Blood* 114:4687-4695, 2009.
143. Yeh, S, Weichel, ED, Faia, LJ, Albini, TA, Wroblewski, KK, Stetler-Stevenson, M, Ruiz, P, Sen, HN, Chan, CC, Nussenblatt, RB: 25-gauge transconjunctival sutureless vitrectomy for the diagnosis of intraocular lymphoma. *British Journal of Ophthalmology*, 94:633-638, 2010.
144. Wayne, AS, Kreitman, RJ, Findley, HW, Lew, G, Delbrook, C, Steinberg, SM, Stetler-Stevenson, M, FitzGerald, DJ, Pastan, I: Anti-CD22 Immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-Positive Hematologic Malignancies of Childhood: Preclinical Studies and Phase I Clinical Trial. *Clin Cancer Res* 16:1894-1903, 2010.
145. Mussai, F, Campana, D, Bhojwani, D, Stetler-Stevenson, M, Steinberg, SM, Wayne, AS, Pastan, I : Cytotoxicity of the anti-CD22 immunotoxin HA22 (CAT-8015) against paediatric acute lymphoblastic leukaemia. *British Journal of Haematology*, 150:352-358, 2010
146. Sportes, C, Babb, RR, Krumlauf, MC, Hakim, FT, Steinberg, SM, Chow, CK, Brown, MR, Fleisher, TA, Noel, P, Maric, I, Stetler-Stevenson, M, Engel, J, Buffet, R, Morre, M, Amato, RJ, Pecora, A, Mackall, CL, Gress, RE: Phase I Study of Recombinant Human Interleukin-7 Administration in Subjects with Refractory Malignancy. *Clin Cancer Res* 16:727-735, 2010.
147. Wang, L, Abbasi, F, Jasper, GA, Kreitman, RJ, Liewehr, D, Marti, GE, Stetler-Stevenson, M: Variables in the Quantification of CD4 in Normals and Hairy Cell Leukemia Patients. *Clinical Cytometry* 80B: 51-57, 2010.
148. Morisot S, Wayne AS, Bohana-Kashtan O, Kaplan IM, Gocke CD, Hildreth R, Stetler-Stevenson M, Walker RL, Davis S, Meltzer PS, Wheelan SJ, Brown P, Jones RJ, Shultz LD, Civin CI. High frequencies of leukemia stem cells in poor-outcome childhood precursor-B acute lymphoblastic leukemias. *Leukemia* 24:1859-66, 2010.
149. Perez-Galan, P, Mora-Jensen, H, Weniger, MA, Shaffer, AL, Rizzatti, EG, Chapman, CM, Mo, CC, Stennett, LS, Rader, C, Liu, P, Raghavachari, N, Stetler-Stevenson, M, Yuan, CM, Pittaluga, S, Maric, I, Dunleavy, KM, Wilson, WH, Staudt, LM, Wiestner, A. Bortezomib resistance in Mantle Cell Lymphoma is associated with plasmacytic differentiation, *BLOOD*, *Blood*, 117:542-52, 2011.
150. Jasper, GA, Arun, I, Venzon, D, Kreitman, RJ, Wayne, A., Yuan, CM, Marti, GE, Stetler-Stevenson, M: Variables Affecting the Quantitation of CD22 in Neoplastic B Cells. *Clinical Cytometry*, Epub (<http://dx.doi.org/10.1002/cyto.b.20567>) September 15, 2010, *Cytometry B Clin Cytom*, 80:83-90, 2011.

151. Herishanu, Y, Perez-Galan, P, Liu, D, Biancotto, A, Pittaluga, S, Vire, B, Gibellini, F, Njuguna, N, Lee, E, Stennett, L, Raghavachari, N, Liu, P, McCoy, JP, Raffeld, M, Stetler-Stevenson, M, Yuan, C, Sherry, R, Arthur, DC, Maric, I, White, T, Marti, GE, Munson, P, Wilson, W, Wiestner, A. The lymph node microenvironment promotes B-cell receptor signaling, NF kappa B activation, and tumor proliferation in chronic lymphocytic leukemia. *BLOOD*, 117:563-574, 2011.
152. Kochenderfer, Wilson, WH, Janik, JE, Dudley, ME, Nathan, DA, Stetler-Stevenson, M., Maric, I., Raffeld, M., Lanier, BJ, Rosenberg, SA: Eradication of B-lineage cells and regression of lymphoma and in a patient treated with autologous T cells genetically-engineered to recognize CD19. *Blood*, 116:4099-102, 2010
153. Arun, I, Wulu, J.A., Janik, J. E., Jasper, G. A., C.M. Yuan, C.M., Venzon, D., Stetler-Stevenson, M.. Visual Inspection Versus Quantitative Flow Cytometry to Detect Aberrant CD2 Expression in Malignant T Cells. *Clinical Cytometry*, 78B:169-175, 2010.
154. Tembhare, P., Yuan, C.M., Xi L., Morris J.C., Liewehr, D, David Venzon, D, Janik, J.E., Raffeld M., Stetler-Stevenson M. Flow Cytometric Immunophenotypic Assessment of T-cell Clonality by V Beta Repertoire Analysis: Detection of T Cell Clonality at Diagnosis and Monitoring of Minimal Residual Disease Following Therapy. *AJCP*, 135:890-900, 2011.
155. Degheidy, H.A., David J.Venzon, D., Farooqui, M.Z.H., Abbasi, F., Arthur, D.C., Wiestner, A., Stetler-Stevenson, M., Marti, G.E. Methodological Comparison of Two Anti-Zap-70 Antibodies. *Clinical Cytometry*, 80B:300-308, 2011.
156. Degheidy, H.A., David J.Venzon, D., Farooqui, M.Z.H., Abbasi, F., Arthur, D.C., Wilson, W., Wiestner, A., Stetler-Stevenson, M., Marti, G.E. Improved ZAP-70 Assay Using Two Clones and Multiple Methods of Analysis. *Clinical Cytometry* 80B:309-317, 2011.
157. Kreitman, R J, Arons, E, Stetler-Stevenson, M, FitzGerald , DJP, Wilson, W, Pastan, I. Recombinant immunotoxins and other therapies for relapsed/refractory HCL. *Leukemia and Lymphoma*, 52:82-86, 2011.
158. Marti, GE, Stetler-Stevenson, M, Drbohlav-Grant, N, White, T, Figg, WD, Tohnya, T, Jaffe, ES, Dunleavy, K, Janik, JE, Steinberg, SM, Wilson, WH, Phase I Trial of 7-Hydroxystaurosporine (UCN-01) and Fludarabine Phosphate (FAMP): In Vitro Evidence of UCN-01 Induced Apoptosis in CLL. *Leuk Lymphoma*, 52: 2284-2292, 2011.
159. Tembhare, P., Yuan, C.M., Morris J.C., D, Janik, J.E., Filie, AC, Stetler-Stevenson M. Flow Cytometric Immunophenotypic Assessment of T-cell Clonality by V Beta Repertoire Analysis in Fine Needle Aspirates and Cerebrospinal Fluid. *AJCP* 137:220-226. 2012.
160. Venkataraman, G, Aguhar, C, Kreitman, R, Yuan, CM. Stetler-Stevenson, M. Characteristic CD103 and CD123 expression pattern defines hairy cell leukemia: utility

of CD123 and CD103 in diagnosis of mature B-cell lymphoproliferative disorders. *AJCP*, 136:625-630, 2011.

161. Calvo KR, Vinh DC, Maric I, Wang W, Noel P, Stetler-Stevenson M, Arthur DC, Raffeld M, Dutra A, Pak E, Myung K, Hsu AP, Hickstein DD, Pittaluga S, Holland SM. Myelodysplasia in autosomal dominant and sporadic monocytopenia immunodeficiency syndrome: diagnostic features and clinical implications. *Haematologica* 96:221-5, 2011.
162. Stetler-Stevenson M, Tembhare PR. Diagnosis of hairy cell leukemia by flow cytometry. *Leuk. Lymphoma* 52 Suppl 2:11-3, 2011.
163. Kreitman RJ, Arons E, Stetler-Stevenson M, Miller KB. Response of hairy cell leukemia to bendamustine. *Leuk. Lymphoma* 52:153-6, 2011.
164. Arons E, Roth L, Sapolsky J, Suntum T, Stetler-Stevenson M, Kreitman RJ. Evidence of canonical somatic hypermutation in hairy cell leukemia. *Blood* 117:844-51, 2011.
165. Yuan CM, Stetler-Stevenson M. Role of flow cytometry of peripheral blood and bone marrow aspirates in early myeloma. *Semin. Hematol.* 48:32-8, 2011.
166. Calvo KR, McCoy CS, Stetler-Stevenson M. Flow cytometry immunophenotyping of hematolymphoid neoplasia. *Methods Mol. Biol.* 699:295-316, 2011.
167. Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, Stetler-Stevenson M, Phan GQ, Hughes MS, Sherry RM, Yang JC, Kammula US, Devillier L, Carpenter R, Nathan DA, Morgan RA, Laurencot C, Rosenberg SA. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. *Blood*. 2012 Mar 22;119(12):2709-20. doi: 10.1182/blood-2011-10-384388. Epub 2011 Dec 8.
168. Shah, N, Bacher, U, Fry, T, Calvo, KR, Stetler-Stevenson, M, Arthur, DC, Kurlander, R, Baird, K, Wise, B, Giralt, S, Bishop, M., Hardy, NM, Wayne, AS. Solving Clinical Problems in Blood Diseases: Myelodysplastic Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation: Diagnostic and Therapeutic Challenges. *American Journal of Hematology*. 87:916-922, 2012
169. Degheidy, HA, Venzon, DJ, Farooqui, MZH, Abbasi, F, Arthur, DC, Wilson, WH, Wiestner, A, Stetler-Stevenson, M, Marti, GE. Combined Normal Donor and CLL: Single Tube ZAP-70 Analysis. *Clinical Cytometry: Cytometry PartB*. 82B:67-77, 2012.
170. Haso, W, Lee, DW, Shah, NN, Stetler-Stevenson, M, Yuan, CM, Pastan, IH, Dimitrov, DS, Morgan, RA, FitzGerald, DJ, Barrett, DM, Wayne, AS, Mackall, CL, Orentas, RJ: Anti-CD22-Chimeric Antigen Receptors Targeting B Cell Precursor Acute Lymphoblastic Leukemia. *Blood*. 121:1165-1174, 2013.
171. Shao H, Calvo KR, Grönborg M, Tembhare PR, Kreitman RJ, Stetler-Stevenson M, Yuan CM. Distinguishing hairy cell leukemia variant from hairy cell leukemia: Development and validation of diagnostic criteria. *Leukemia Research*. *Blood*. 2013 Feb 14;121(7):1165-74. doi: 10.1182/blood-2012-06-438002. Epub 2012 Dec 14. <http://dx.doi.org/10.1016/j.leukres.2012.11.021>

172. Kreitman RJ, Tallman MS, Robak T, Coutre S, Wilson WH, Stetler-Stevenson M, FitzGerald DJ, Lechleider R, Pastan I. Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia. *Journal of Clinical Oncology* 2012;30:1822-1828.
173. Tembhare P, Yuan CM, Xi LQ, Marti G, Raffeld M, Stetler-Stevenson M. Case study interpretation-Portland: Case 1. *Cytometry Part B-Clinical Cytometry* 2012;82B:177-179.
174. Xi LQ, Arons E, Navarro W, Calvo KR, Stetler-Stevenson M, Raffeld M, Kreitman RJ. Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation. *Blood* 2012;119:3330-3332.
175. Hardy NM, Fellowes V, Rose JJ, Odom J, Pittaluga S, Steinberg SM, Blacklock-Schuver B, Avila DN, Memon S, Kurlander RJ and others. Costimulated tumor-infiltrating lymphocytes are a feasible and safe alternative donor cell therapy for relapse after allogeneic stem cell transplantation. *Blood* 2012;119:2956-2959.
176. Shaffer BC, Modric M, Stetler-Stevenson M, Arthur DC, Steinberg SM, Liewehr DJ, Fowler DH, Gale RP, Bishop MR, Pavletic SZ. Rapid complete donor lymphoid chimerism and graft-versus-leukemia effect are important in early control of chronic lymphocytic leukemia. *Exp Hematol*. 2013 May 18. doi:pii: S0301-472X(13)00219-1. 10.1016/j.exphem.2013.04.015. [Epub ahead of print]
177. Greig B, Stetler-Stevenson M, Lea J. Stabilization media increases recovery in paucicellular cerebrospinal fluid specimens submitted for flow cytometry testing. *Cytometry B Clin Cytom*. 2013 May 14. doi: 10.1002/cyto.b.21096. [Epub ahead of print, 2014;86:135-138.
178. Degheidy HA, Gadalla SM, Farooqui MZ, Abbasi F, Arthur DC, Bauer SR, Wilson WH, Wiestner A, Stetler-Stevenson MA, Marti GE. Bcl-2 level as a biomarker for 13q14 deletion in CLL. *Cytometry B Clin Cytom*. 2013 Jul;84(4):237-47. doi: 10.1002/cyto.b.21090. Epub 2013 May 14.
179. Klion AD, Mejia R, Cowen EW, Dowdell KC, Dunleavy K, Fahle GA, Holland-Thomas N, Maric I, Pittaluga S, Raffeld M, Santos C, Stetler-Stevenson M, Krogmann T, Shatzer AN, Turk SP, Yin Y, Xi L, Prussin C, Cohen JI. Chronic active Epstein-Barr virus infection: a novel cause of lymphocytic variant hypereosinophilic syndrome. *Blood*. 2013 Mar 21;121(12):2364-6. doi: 10.1182/blood-2012-12-472720.
180. Manasanch EE, Braylan R, Stetler-Stevenson M, Yuan C, Gounden V, Korde N, Tageja N, Bhutani M, Calvo K, Maric I, Roschewski M, Staudt LM, Landgren O. Lack of MYD88 L265P in non-IgM lymphoplasmacytic lymphoma. *Leuk Lymphoma*. 2013 Aug 5. [Epub ahead of print], PMID: 23915224

181. Flanders A, Stetler-Stevenson, M, Landgren, O. Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity. *Blood*. 2013;122:1088-1089. Doi:10.1182/blood-2013-05-506170.
182. Tembhare, RT, Marti, G, Wiestner, A, Degheidy, H, Farooqui, M, Kreitman, RJ, Jasper, GA, Yuan, CM, Liewehr, D, Venzon, D, Stetler-Stevenson, M. Quantification of Expression of Antigens Targeted by Antibody Based Therapy in Chronic Lymphocytic Leukemia. *AJCP*, 2013; 140:813-818.
183. Cherry BM, Korde N, Kwok M, Manasanch EE, Bhutani M, Mulquin M, Zuchlinski D, Yancey MA, Maric I, Calvo KR and others. Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study. *Leukemia & Lymphoma* 2013;54:2215-2218.
184. Kreitman RJ, Wilson W, Calvo KR, Arons E, Roth L, Sapolsky J, Zhou H, Raffeld M, Stetler-Stevenson M. Cladribine with Immediate Rituximab for the Treatment of Patients with Variant Hairy Cell Leukemia. *Clinical Cancer Research* 2013;19:6873-6881.
185. Burotto M, Stetler-Stevenson M, Arons E, Zhou H, Wilson W, Kreitman RJ. Bendamustine and Rituximab in Relapsed and Refractory Hairy Cell Leukemia. *Clinical Cancer Research* 2013;19:6313-6321.
186. Santiago M, Salem DA, Addison MM, Yuan CM, Jasper GA, Stetler-Stevenson M. FLOW CYTOMETRIC CLL MRD TESTING: IMPACT OF PANEL DESIGN, AND AUTOMATED CELL PROCESSING ON SENSITIVITY. *Cytometry Part B-Clinical Cytometry* 2013;84:420-420.
187. Tembhare PR, Yuan CM, Venzon D, Braylan R, Korde N, Manasanch E, Zuchlinsky D, Calvo K, Kurlander R, Bhutani M, Tajeja, N., Maric, I., Mulquin, M., Roschewski, M., Kwok, M., Liewehr, D., Landgren, O., Stetler-Stevenson, M.. Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases. *Leukemia Research* 2014; 38:371-376
188. Roschewski, M., Stetler-Stevenson, M., Yuan, C., Mailankody, S. , Korde, N., Landgren, O.. Minimal Residual Disease: What Are the Minimum Requirements? *JCO* 2014; 32: 475-476
189. Stetler-Stevenson, M.. Monoclonal B-cell lymphocytosis in donors. *Blood* 2014; 123: 1281-1282.
190. Wilson WH, Bromberg JE, Stetler-Stevenson M, Steinberg SM, Martin-Martin L, Muñoz C, Sancho J, Caballero MD, Davidis MA, Brooimans RA, Sanchez-Gonzalez B, Salar A, González-Barca E, Ribera JM, Shovlin M, Filie A, Dunleavy K, Mehrling T, Spina M, Orfao A. .Detection and outcome of occult leptomeningeal disease in diffuse large B-cell lymphoma and Burkitt lymphoma. *Haematologica*. [Epub ahead of print], 2014.

191. Korde N, Carlsten M, Lee M, Minter A, Tan E, Kwok M, Manasanch E, Bhutani M, Tajeja N, Roschewski M, Zingone A, Costello R, Mulquin M, Zuchlinski D, Maric I, Calvo KR, Braylan R, Tembhare P, Yuan C, Stetler-Stevenson M, Trepel J, Childs R, Landgren O.. A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma. *Haematologica*. [Epub ahead of print], 2014; 99:81-83.
192. Landgren, O, Gormley, N, Turley, D, Owen, RG, Rawstron, A, Paiva, B, Barnett, D, Arroz, M, Wallace, P, Durie, B, Yuan, C, Dogan, A, Stetler-Stevenson, M, Marti, GE:Flow Cytometry Detection of Minimal Residual Disease in Multiple Myeloma: Lessons Learned at FDA-NCI Roundtable Symposium. *American Journal of Hematology*. 89: 1159-60, 2014.
193. Manasanch, E, Salem, DA, Yuan, CM, Tajeja, N, Bhutani, M, Kwok, M, Kazandjian, D, Carter, G, Steinberg, SM, Zuchlinski, D, Mulquin, M, Calvo, K, Maric, I, Roschewski, M, Korde, N, Braylan, R, Landgren, O, Stetler-Stevenson, M. Flow cytometric sensitivity and characteristics of plasma cells in patients with multiple myeloma or its precursor disease: influence of biopsy site and anticoagulation method. *Leukemia and Lymphoma*. September 27, 2014. (doi:10.3109/10428194.2014.955020)
194. Sham Mailankody, Neha Korde, Alexander Lesokhin, Nikoletta Lendvai, Hani Hassoun, Maryalice Stetler-Stevenson, and Ola Landgren. Minimal Residual Disease in Multiple Myeloma: Bringing the Bench to the Bedside. *Nature Reviews Clinical Oncology* 2015;12:286-U139.
195. Berkowitz JL, Janik JE, Stewart DM, Jaffe ES, Stetler-Stevenson M, Shih JH, Fleisher TA, Turner M, Urquhart NE, Wharfe GH, Figg, WD, Peer, CJ, Goldman, CK, Waldmann, TA, Morris, JC. Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma. *Clinical Immunology* 2014;155:176-187.
196. Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YZK, Delbrook C, Feldman SA, Fry TJ, Orentas R, Sabatino M, Shah NN and others. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. *Lancet* 2015;385:517-528.
197. Korde N, Roschewski M, Zingone A, Kwok M, Elisabet E Manasanch, Manisha Bhutani, Nishant Tajeja, Dickran Kazandjian, Mailankody, S, Wu, P, Morrison, C, Costello R, Zhang, Y, Burton, D, Mulquin, M, Zuchlinski D, Lamping, L, Carpenter, A, Wall, Y, Carter, G, Cunningham, SC, Gounden, V, Sissung, TM, Peer, C, Maric, I, Calvo, K, Braylan, R, Yuan, C, Stetler-Stevenson, M, Arthur, DC, Kong, KA, Weng, L, Faham, M, Lindenberg, L, Kurdzial, K, Choyke, P, Steinberg, SM, Figg, W, Landgren, O. Treatment with Carfilzomib-Lenalidomide-Dexamethasone with Lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma. *JAMA Oncol* 2015 (doi:[10.1001/jamaoncol.2015.2010](https://doi.org/10.1001/jamaoncol.2015.2010)).

198. Kochenderfer James N, Dudley Mark E, Kassim Sadik H, Somerville Robert P T, Carpenter Robert O, Stetler-Stevenson Maryalice, Yang James C, Phan Giao Q, Hughes Marybeth S, Sherry Richard M, Raffeld Mark, Feldman Steven, Lu Lily, Li Yong F, Ngo Lien T, Goy Andre, Feldman Tatyana, Spaner David E, Wang Michael L, Chen Clara C, Kranick Sarah M, Nath Avindra, Nathan Debbie-Ann N, Morton Kathleen E, Toomey Mary Ann, Rosenberg Steven A. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. *J. Clin. Oncol.* 33: 540-9, 2015
199. Stetler-Stevenson Maryalice, Paiva Bruno, Stoolman Lloyd, Lin Pei, Jorgensen Jeffrey L, Orfao Alberto, Van Dongen Jacques, Rawstron Andy C. Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition. *Cytometry B Clin Cytom.* 90B:26-30, 2016.
200. Rawstron, AC, Paiva Bruno, Stetler-Stevenson Maryalice, Assessment of Minimal Residual Disease in Myeloma and the Need for a Consensus Approach. *Cytometry B Clin Cytom.* 90B:21-26, 2016.
201. Farooqui Mohammed Z H, Valdez Janet, Martyr Sabrina, Aue Georg, Saba Nakhle, Niemann Carsten U, Herman Sarah E M, Tian Xin, Marti Gerald, Soto Susan, Hughes Thomas E, Jones Jade, Lipsky Andrew, Pittaluga Stefania, Stetler-Stevenson Maryalice, Yuan Constance, Lee Yuh Shan, Pedersen Lone B, Geisler Christian H, Calvo Katherine R, Arthur Diane C, Maric Irina, Childs Richard, Young Neal S, Wiestner Adrian. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. *Lancet Oncol.* 16: 169-76, 2015.
202. Kranick Sarah M, Goncalves Priscila H, Stetler-Stevenson Maryalice, Aleman Karen, Polizzotto Mark N, Little Richard F, Yarchoan Robert, Uldrick Thomas S. Paradoxical central nervous system immune reconstitution syndrome in acquired immunodeficiency syndrome-related primary central nervous system lymphoma.. *Haematologica.* 100: e21-4, 2015.
203. Kreitman, RJ, Stetler-Stevenson, M, Jaffee, ES, Conlon, KC, Steinberg, SM, Wilson, W, Waldman, TS, Pastan, I. Complete emission of adult T-cell leukemia with anti-CD25 recombinant immunotoxin LMB-2 and chemotherapy to block immunogenicity. *Clinical Cancer Research.* 22:310-318, 2016.
204. Rawstron AC, Fazi C, Agathangelidis A, Villamor N, Letestu R, Nomdedeu J, Palacio C, Stehlikova O, Kreuzer KA, Liptrot S, O'Brien D, de Tute RM, Marinov I, Hauwel M, Spacek M, Dobber J, Kater AP, Gambell P, Soosapilla A, Lozanski G, Brachtl G, Lin K, Boysen J, Hanson C, Jorgensen JL, Stetler-Stevenson M, Yuan C, Broome HE, Rassenti L, Craig F, Delgado J, Moreno C, Bosch F, Egle A, Doubek M, Pospisilova S, Mulligan S, Westerman D, Sanders CM, Emerson R, Robins HS, Kirsch I, Shanafelt T, Pettitt A, Kipps TJ, Wierda WG, Cymbalista F, Hallek M, Hillmen P, Montserrat E, Ghia P. A

complementary role of multiparameter flow-cytometry and high-throughput sequencing for minimal residual disease (MRD) detection in chronic lymphocytic leukemia (CLL): An european research initiative on CLL (ERIC) study. *Leukemia*.30:929-936, 2016.

205. Skarzynski M, Niemann CU, Lee YS, Martyr S, Maric I, Salem D, Stetler-Stevenson M, Marti GE, Calvo KR, Yuan C and others. Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy. *Clinical Cancer Research* 2016;22:86-95.
206. Sun C, Tian X, Lee YS, Gunti S, Lipsky A, Herman SEM, Salem D, Stetler-Stevenson M, Yuan C, Kardava L and others. Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib. *Blood* 2015;126:2213-2219.
207. Nieman CU, Herman SEM, Maric I, Gomez-Rodriguez J, Biancotto A, Chang BY, Martyr S, Stetler-Stevenson M, Yuan CM, Calvo KR and others. Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib - Findings from an Investigator-Initiated Phase II Study. *Clinical Cancer Research* 2016;22:1572-1582.
208. Kreitman RJ, Arons E, Still K, Tallman MS, Stetler-Stevenson M, Yuan C, Fitzgerald DJP, Pastan I. Moxetumomab pasudotox and minimal residual disease in hairy cell leukemia. *Journal of Clinical Oncology* 2015;33:1.
209. Degheidy H, Salem DAA, Yuan CM, Stetler-Stevenson MA. 2016. Chronic lymphocytic leukemia, the prototypic chronic leukemia for flow cytometric analysis, p 226-234. In Detrick B, Schmitz JL, Hamilton RG (ed), *Manual of Molecular and Clinical Laboratory Immunology*, 8th ed. ASM Press, Washington, DC.
210. Manasanch Elisabet E, de Larrea Carlos Fernández, Zingone Adriana, Steinberg Seth M, Kwok Mary, Tageja Nishant, Bhutani Manisha, Kazandjian Dickran, Roschewski Mark, Wu Peter, Carter George, Zuchlinski Diamond, Mulquin Marcia, Lamping Liz, Costello Rene, Burton Deborah, Gil Lindsay A, Figg William D, Maric Irina, Calvo Katherine R, Yuan Constance, Stetler-Stevenson Maryalice, Korde Neha, Landgren Ola. Circulating plasma proteasome in newly diagnosed multiple myeloma. *Leukemia and Lymphoma*, 2017;58:639-645.
211. Ali, S.A., et al., T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. *Blood*, 2016. **128**(13): p. 1688-1700.
212. Preffer, F.I., et al., Introduction to Multiple Myeloma Special Issue: The Flow Cytometric Detection of Minimal Residual Disease. *Cytometry Part B-Clinical Cytometry*, 2016. **90**(1): p. 9-13.

213. Xiao, W.B., et al., Hypereosinophilic Syndrome with Clonal T-cell Receptor Gene Rearrangement: A Retrospective Study of 51 Patients. *Modern Pathology*, 2016. **29**: p. 385A-385A.
214. Ahn IE, Albitar A, Underbayev C, Herman S, Tian X, Soto S, Stetler-Stevenson M, Maric I, Farooqui MZ, Albitar M, Wiestner A. Integrated analysis of ibrutinib resistance in chronic lymphocytic leukemia. *Cancer Research*. 2016;76:3.
215. Khanna S, Mussai F, Thomas A, Middleton G, Yuan C, Morrow B, Zhang JL, Pastan I, Stetler-Stevenson M, Hassan R. Granulocytic MDSCs (CD11b+CD15+CD14-HLADR-) in peripheral blood of mesothelioma patients are elevated and suppress T cell proliferation and function via reactive oxygen species. *Cancer Research*. 2016;76:3.
216. Salem D, Stetler-Stevenson M, Yuan C, Landgren O. Myeloma minimal residual disease testing in the United States: Evidence of improved standardization. *American Journal of Hematology*. 2016;91(12):E502-E3.
217. Wolniak Kristy, Goolsby Charles, Choi Sarah, Ali Asma, Serdy Nina, Stetler-Stevenson Maryalice. Report of the results of the international clinical cytometry society and american society for clinical pathology workload survey of clinical flow cytometry laboratories. *Cytometry B Clin Cytom*. 2017; 92:525-533.
218. Sharma K, Janik JE, O'Mahony D, Stewart D, Pittaluga S, Stetler-Stevenson M, Jaffe ES, Raffeld M, Fleisher TA, Lee CC, Steinberg SM, Waldmann TA, Morris JC. Phase II Study of Alemtuzumab (CAMPATH-1) in Patients with HTLV-1-Associated Adult T-cell Leukemia/lymphoma. *Clinical Cancer Research*. 2017;23(1):35-42.
219. Ahn IE, Underbayev C, Albitar A, Herman SEM, Tian X, Maric I, Arthur D, Wake L, Pittaluga S, Yuan CM, Stetler-Stevenson M, Soto S, Valdez J, Albitar M, Wiestner A. Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia. *Blood*. 2017;129(11):1469-79.
220. Salem D, Korde N, Venzon D, Liewehr D, Maric, I, Calvo, K, Braylan, R, Tembhare PR, Yuan CM, Landgren CO, Stetler-Stevenson M. Detection of Expression of the IL-6 Receptor Alpha Chain (CD126) in Normal and Abnormal Plasma Cells in Monoclonal Gammopathy of Uncertain Significance and Smoldering Myeloma. *Leuk Lymphoma*. 2018; 59:178-186, <http://dx.doi.org/10.1080/10428194.2017.1321746>.
221. Keeney Michael, Wood Brent L, Hedley Benjamin D, DiGiuseppe Joseph A, Stetler-Stevenson Maryalice, Paietta Elisabeth, Lozanski Gerard, Seegmiller Adam C, Greig Bruce W, Shaver Aaron C, Mukundan Lata, Higley Howard R, Sigman Caroline C, Kelloff Gary, Jessup J Milburn, Borowitz Michael J. A QA program for MRD testing demonstrates that systematic education can reduce discordance among experienced interpreters. *Cytometry B Clin Cytom*. 2017. PMID: 28475275

222. Lionakis Michail S, Dunleavy Kieron, Roschewski Mark, Widemann Brigitte C, Butman John A, Schmitz Roland, Yang Yandan, Cole Diane E, Melani Christopher, Higham Christine S, Desai Jigar V, Ceribelli Michele, Chen Lu, Thomas Craig J, Little Richard F, Gea-Banacloche Juan, Bhaumik Sucharita, Stetler-Stevenson Maryalice, Pittaluga Stefania, Jaffe Elaine S, Heiss John, Lucas Nicole, Steinberg Seth M, Staudt Louis M, Wilson Wyndham H. Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma." *Cancer Cell* 2017;31:833-843.e5
223. Herndon T M, Chen S-S, Saba N S, Valdez J, Emson C, Gatmaitan M, Tian X, Hughes T E, Sun C, Arthur D C, Stetler-Stevenson M, Yuan C M, Niemann C U, Marti G E, Aue G, Soto S, Farooqui M Z H, Herman S E M, Chiorazzi N, Wiestner A. Direct in vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral blood. *Leukemia*. 2017; 31:1340-1347.
224. Xiao, W, Salem, D, McCoy, C, Lee, D, Shah, N, Stetler-Stevenson, M, Yuan, CM. Early recovery of circulating immature B cells in B-lymphoblastic leukemia patients after CD19 targeted CAR T cell therapy: a pitfall for minimal residual disease detection. *Cytometry: Part B-Clinical Cytometry*. 2018; 94:434-443.
225. Terry J. Fry M.D., Nirali N. Shah M.D., Rimas J. Orentas Ph.D., Maryalice Stetler-Stevenson M.D., Ph.D., Constance M. Yuan M.D., Ph.D., Sneha Ramakrishna, M.D., Pamela Wolters Ph.D., Staci Peron-Martin Ph.D., Cindy Delbrook R.N., Bonnie Yates P.N.P., Haneen Shalabi, D.O., Thomas J. Fountaine M.D., Jack F. Shern M.D., Robbie G. Majzner, M.D., David F. Stroncek M.D., Marianna Sabatino M.D., Yang Feng, Ph.D., Dimiter S. Dimitrov, Ph.D, Ling Zhang Ph.D., Sang Nguyen, Haiying Qin M.S., Boro Dropulic, Ph.D., Daniel W. Lee M.D., and Crystal L. Mackall M.D. CD22-CAR T Cells Induce Remissions in CD19-CAR Naïve and Resistant B-ALL. *Nature Medicine* (2018; 24,1-20.
226. Mailankody S, Kazandjian D, Korde N, Roschewski M, Manasanch E, Bhutani M, et al. Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma. *Blood Advances*. 2017;1(22):1911-8.
227. Wayne AS, Shah NN, Bhojwani D, Silverman LB, Whitlock JA, Stetler-Stevenson M, et al. Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia. *Blood*. 2017;130(14):1620-7.
228. Ahn, I; Tian, X; Soto, S; Nierman, P ; Valdez, J ; Maric, I; Stetler-Stevenson, M ; Yuan, C; Marti, G ; Wiestner, A. Combination of ibrutinib and short-course fludarabine in previously untreated patients with CLL/SLL: a result of a pilot phase II study. *Leukemia and Lymphoma* 2017;58:20-21.
229. Landgren, C.O. Combination therapy with carfilzomib, lenalidomide and dexamethasone (KRd) results in an unprecedented purity of the stem cell graft in newly diagnosed patients with myeloma. *Bone Marrow Transplantation*. (accepted).

230. Kreitman, R J, Tallman, MS, Robak, T, Coutre, S, Wilson, W, Stetler-Stevenson, M, FitzGerald, DJ, Santiago, L, Gao, G, Lanasa, M C, Pastan, I. Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up. *Blood* 2018; 131: 2331-2334.
231. Ahn, IE, Farooqui, MZH, Tian, X, Valdez, J, Sun, C, Soto, S, Lotter, J, Housel, S, Stetler-Stevenson, M, Yuan, CM, Maric, I, Calvo, KR, Nierman, P, Hughes, TE, Saba, NS, Marti, GE, Pittaluga, S, Herman, SEM, Niemann, C, Pedersen, LB, Geisler, CH, Childs, R, Aue, G, Wiestner, A. Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study. *Blood* 2018; 131: 2357-2366.
232. Brudno Jennifer N, Maric Irina, Hartman Steven D, Rose Jeremy J, Wang Michael, Lam Norris, Stetler-Stevenson Maryalice, Salem Dalia, Yuan Constance, Pavletic Steven, Kanakry Jennifer A, Ali Syed Abbas, Mikkilineni Lekha, Feldman Steven A, Stroncek David F, Hansen Brenna G, Lawrence Judith, Patel Rashmika, Hakim Frances, Gress Ronald E, Kochenderfer James N. T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma. *J. Clin. Oncol.* JCO2018778084, 2018.
233. Tajeja Nishant, Korde Neha, Kazandjian Dickran, Panch Sandhya, Manasanch Elisabet, Bhutani Manisha, Kwok Mary, Mailankody Sham, Yuan Constance, Stetler-Stevenson Maryalice, Leitman Susan F, Sportes Claude, Landgren Ola. Combination therapy with carfilzomib, lenalidomide and dexamethasone (KRd) results in an unprecedented purity of the stem cell graft in newly diagnosed patients with myeloma. *Bone Marrow Transplant.* 2018.
234. Khanna Swati, Graef Suzanne, Mussai Francis, Thomas Anish, Wali Neha, Yenidunya Bahar Guliz, Yuan Constance, Morrow Betsy, Zhang Jingli, Korangy Firouzeh, Gretten Tim F, Steinberg Seth M, Stetler-Stevenson Maryalice, Middleton Gary, De Santo Carmela, Hassan Raffit. Tumor-Derived GM-CSF Promotes Granulocyte Immunosuppression in Mesothelioma Patients. *Clin. Cancer Res.* 24: 2859-2872, 2018.
235. Müller Fabian, Cunningham Tyler, Stookey Stephanie, Tai Chin-Hsien, Burkett Sandra, Jailwala Parthav, Stetler-Stevenson Maryalice, Cam Margaret C, Wayne Alan S, Pastan Ira. 5-Azacytidine prevents relapse and produces long-term complete remissions in leukemia xenografts treated with Moxetumomab pasudotox. *Proc. Natl. Acad. Sci. U.S.A.* 115: E1867-E1875, 2018. [Journal].
236. Shalabi Haneen, Kraft Ira L, Wang Hao-Wei, Yuan Constance M, Yates Bonnie, Delbrook Cindy, Zimbelman Julie D, Giller Roger, Stetler-Stevenson Maryalice, Jaffe Elaine S, Lee Daniel W, Shern Jack F, Fry Terry J, Shah Nirali N. Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma. *Haematologica.* 103: e215-e218, 2018.